Genezen, Monon Bioventures, and Purdue University partnership to develop glioblastoma therapeutic

Scroll Down

Glioblastoma is one of the most aggressive types of cancer, affecting the brain and spinal cord. Despite patients generally receiving maximum treatment, it is almost always lethal, with cancer often recurring.

In partnership with Monon Bioventures and Purdue University College of Pharmacy, Genezen is honored to be involved in a novel project acting to rectify this.

With a Phase I Small Business Innovation Research (SBIR) grant awarded by the National Cancer Institute, the collaboration aims to leverage Genezen’s extensive lentivirus expertise to demonstrate the manufacturing feasibility of this new therapeutic. Predominantly used in developing chimeric antigen receptor (CAR) T cell therapies targeting various cancers, lentiviral vectors (LVs) have a strong history of revolutionizing gene therapy modalities. The advancement of this unique glioblastoma therapeutic, which modifies natural killer (NK) cells to recognize and mount a response against glioblastomas, highlights LV’s potential to broaden therapeutic horizons.

As an NK-based therapy, this unique use of LVs stands at the frontier of cellular therapy, signifying the anticipated rise of allogeneic therapies. Rather than needing to harvest T cells from each individual patient, as with CAR-T therapies, NK cells can be accepted from multiple donors, dramatically expanding large dose manufacturing capabilities. This translates into helping more patients in shorter timeframes.

Building on the critical preclinical proof of concept work conducted by Sandro Matosevic, the assistant professor in the Department of Industrial and Physical Pharmacy, the Indiana-based partnership aims to progress the discovery to the clinic. Monon Bioventures will work on the treatment with Matosevic’s laboratory at Purdue University and Genezen, situated at Fishers Life Science & Innovation Park. With all partnership members within 100 miles of one another, we can expect this project to see the full advantages of rapid information transfer and tight collaboration.

Link to press release

You may also be interested in...

4 factors driving the trend towards…

The cell and gene therapy (C&GT) space is expanding rapidly. With...

Read more

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more